Remibrutinib Cuts MS Relapses Versus Teriflunomide
Two phase III trials found the BTK inhibitor lowered relapse rates in adults with relapsing multiple sclerosis compared with teriflunomide.
Updated on Nov. 9, 2026 in Stroke

Phase III trials REMODEL-1 and REMODEL-2 randomly assigned 2,007 adults with relapsing multiple sclerosis to remibrutinib or teriflunomide. Annualized relapse rates were significantly lower in the remibrutinib groups over follow-up of up to 30 months.
Why it matters
Relapsing multiple sclerosis requires long-term treatment, and a therapy that reduces relapses more than an established comparator could shape prescribing choices. The findings were presented at MSToronto2026 and published in The Lancet.
The two randomized phase III trials enrolled 2,007 adults, with 1,006 assigned to remibrutinib and 1,001 to teriflunomide over follow-up of up to 30 months. Annualized relapse rates were significantly lower with remibrutinib, though the exact magnitude of the difference and outcomes beyond 30 months remain unreported in the trial summary.
The players
Remibrutinib
Remibrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor being evaluated as a treatment for relapsing multiple sclerosis.
Teriflunomide
Teriflunomide is an established oral disease-modifying therapy for relapsing multiple sclerosis that served as the active comparator in the trials.
The Lancet
The Lancet is a long-established, peer-reviewed general medical journal that published the trial findings.
The details
Researchers ran two identically designed phase III trials that randomly assigned participants to remibrutinib or teriflunomide. The trial results were presented as a late-breaking abstract at MSToronto2026 and later published in The Lancet.
Timeline
Follow-up in the trials ran for up to 30 months.
Findings were presented at MSToronto2026 in Toronto, Canada, on 21-23 October 2026.
Health Landscape
The findings extend the research on Bruton's tyrosine kinase inhibitors in multiple sclerosis, a drug class whose earlier trials raised liver injury concerns. Remibrutinib's reported favorable safety profile against that backdrop marks a potential shift in how this drug class is evaluated for long-term disease control.
For people living with relapsing multiple sclerosis, a therapy that reduces relapses more than teriflunomide could affect long-term treatment decisions with their clinicians. The reported safety profile, free of the liver injury concerns seen with earlier BTK inhibitors, may also matter when weighing options.
The takeaway
A treatment that lowers relapses while avoiding earlier liver safety concerns could widen options for people managing relapsing multiple sclerosis. Patients should discuss how newer therapies compare with their current treatment with a neurologist.
Further reading
Explore more in the Stroke section for related neurological health coverage.
Source note: This article includes information reported by Nature.



